



Number of Drugs under Consideration by pCPA, 3-month quarterly Average, Q1 2019 – Q3 2023



* Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt


Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CADTH data collected from <https://cadth.ca/reimbursement-review-reports>.

Number of new pCPA Negotiations



Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CADTH data collected from <https://cadth.ca/reimbursement-review-reports>.


CADTH Recommendation to pCPA Engagement, All Drugs



* Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt

Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CADTH data collected from <https://cadth.ca/reimbursement-review-reports>.


Number of Active pCPA Negotiations, 3-month Quarterly Average, Q1 2019 – Q3 2023



Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.


Number of Active pCPA Negotiations and Files Under Consideration, 3-month Quarterly Average, Q1 2019 – Q3 2023

Active Negotiations Under Consideration



Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.


pCPA Total Time, All Drugs



N = number of completed negotiations

Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.


Negotiations on BPG target



BPG – Brand Process Guidelines

* 4 of the negotiations concluded <180 days in 2023 Q1 were new indications of an existing product, with 0 days from LOE to LOI


pCPA Total Time, All Drugs




Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.

Negotiations on Brand Process Guidelines Target


2021



2022



2023



* 4 of the negotiations concluded <180 days in 2023 Q1 were new indications of an existing product, with 0 days from LOE to LOI

Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.